Diabetes shouldn’t prevent you from living the life you want. MiniMed® insulin pump systems can take action for you when you need it most - so you can be free to experience life’s exceptional moments.
Looking for better diabetes control? Medtronic is offering patients the opportunity to try a MiniMed system for 6 weeks at no cost!
What you get:
1 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.
^ The Pump Trial Program is available to new customers only. Only one system may be trialed by a pump trial participant. To enroll in the six-week free product trial you must be insulin dependent, must complete insurance verification, and must have a prescription on file. You must sign a legal agreement acknowledging that you will return the product used during the trial within 30 days of the end of the trial if you decide not to continue with pump therapy. You must commit to uploading into CareLink© Personal 3 times (once every two weeks throughout product trial) and opt into the StartRightSM patient support program.
§ Measured as sensor glucose.
‡ Based upon limited sample size and duration of ASPIRE In-Home study.
Prescription device. Not for everyone.
Important Safety Information: MiniMed® 530G System and MiniMed® 630G Systems with SmartGuard™ Technology
The MiniMed 530G and 630G systems with SmartGuard technology are intended for the delivery of insulin and continuous glucose monitoring for the management of diabetes mellitus in persons 16 years of age or older who require insulin. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK portfolio meter* is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK portfolio meter*, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed 530G and 630G systems are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend On Low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider. WARNING: The SmartGuard feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard feature information in the User Guide and discuss proper use of the feature with your healthcare provider. See www.medtronidiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
* The CONTOUR®NEXT LINK Meter is used with the MiniMed 530G system. The CONTOUR®NEXT LINK 2.4 Meter is used with the MiniMed 630G system.
Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.
MiniMed is a registered trademark. © 2016 Medtronic MiniMed, Inc. All Rights Reserved. 940M13982-013 20160801.